Adebrelimab
Capecitabine
China Medical University, ChinaActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
12 Active assets in the Capecitabine cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Seoul National University Hospital | Phase 3 | BB |
Eloxatin Meng Qiu | Phase 3 | BB |
Calcium folinate pentahydrate Meng Qiu | Phase 3 | BB |
FLUOROURACILUM Seoul National University Hospital | Phase 3 | BB |
Cetuximab Meng Qiu | Phase 3 | B |
View all 13 →
Same molecule, other indications
Adebrelimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →